GlassScriptPhysician profile
Kimberly Little
NPI 1902277742
$1,456.46
in general payments reported to CMS, 2019-2025
16 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $556 · 2023: $526 · 2024: $89.84 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $900.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.78 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $229.12 | 2022-2024 | Spravato |
| Neurocrine Biosciences, INC. | $190.61 | 2022-2023 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $124.90 | 2022-2023 | Breztri |
| Csl Behring | $91.53 | 2022-2023 | Hizentra |
| Alkermes, INC. | $87.50 | 2022-2023 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $80.73 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $62.99 | 2022-2024 | Austedo Xr, Uzedy |
| Alexion Pharmaceuticals, INC. | $56.37 | 2022-2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $48.03 | 2022-2023 | Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.30 | 2022 | |
| Kyowa Kirin, INC. | $33.85 | 2023 | Nourianz |
| Lilly USA, LLC | $21.99 | 2023 | Jardiance |
| Lundbeck LLC | $18.62 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $18.03 | 2025 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.